GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
GlobalData on MSN5d
GSK CEO addresses declining trust in vaccines following Trump re-electionGSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...
Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at the Food and Drug ...
Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...
Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, ...
Pharmaceutical Technology on MSN12d
GSK to acquire Chimagen’s CMG1A46 for autoimmune diseaseGlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...
The Wall Street Journal on MSN12d
GSK Profit Rises on HIV, Cancer Treatments But Sales Slip on Weak U.S. Vaccine DemandGSK reiterated its full-year guidance after its new HIV and cancer treatments lifted profit ahead of analysts’ expectations ...
GlobalData on MSN5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.
India's GlaxoSmithKline Pharmaceuticals reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and vaccines.
Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback